24-003787 nhlbi requires the filing of a provisional patent application in order to establish a priority date to an invention covering dual variable domains enhanced HLA-independent T cell receptors…
Ended Awarded Last action
- Contract number
- 75N92024F00002
- Awardee
-
Klarquist Sparkman, LLP UEI C75KZNSK3CL4
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,274
Award facts
- Opportunity
-
- 20KSBIO012124 Solicitation number
- Contract value 100% obligated
- $14,274.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541110 Offices of Lawyers
- PSC
- R418 Support- Professional: Legal
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Portland, OR 97204, USA
Award details come from SAM.gov/FPDS.
About this award
The National Heart, Lung and Blood Institute of the National Institutes of Health awarded a $14,274 firm fixed price delivery order to Klarquist Sparkman, LLP under the NIH Patent Legal Services master IDIQ contract. The delivery order requires Klarquist Sparkman to file a provisional patent application on behalf of the NHLBI to establish priority for an invention covering enhanced HLA-independent T cell receptors modified T cells targeting a CT-RCC-1 peptide derived to treat cancer. Work will be performed by Klarquist Sparkman in Portland, Oregon over a four month period ending in March 2024. The award provides patent legal services to the NHLBI, which conducts research to prevent and treat heart, lung, blood, and sleep disorders and diseases through basic and clinical research, epidemiology, and health communications.
Description
24-003787 nhlbi requires the filing of a provisional patent application in order to establish a priority date to an invention covering dual variable domains enhanced HLA-independent T cell receptors modified T cells targeting CT-RCC-1 peptide derived
Quick answers
Who was awarded contract 75N92024F00002?
75N92024F00002 was awarded to Klarquist Sparkman, LLP by National Heart Lung and Blood Institute (National Institutes of Health) on December 14, 2023.
How much is contract 75N92024F00002 worth?
The government has obligated $14,274 on 75N92024F00002.
Is contract 75N92024F00002 an order under another contract?
Yes. 75N92024F00002 is a delivery order under 75N98020D00049, an indefinite delivery contract, on NIH Patent Legal Services.
Was contract 75N92024F00002 competed?
The extent of competition for 75N92024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award